• Bomberger, C., Singh-Jairam, M., Rodey, G., Guerriero, A., Yeager, A.M., Fleming, W.H., Holland, H.K. & Waller, E.K. (1998) Lymphoide reconstitution after autologous PBMC transplantation with Facs-sorted CD34+ hematopoietic progenitors. Blood, 91, 25882600.
  • Cabezudo, E., Matutes, E., Ramrattan, M., Morilla, R. & Catovsky, D. (1997) Analysis of residual disease in chronic lymphocytic leukemia. Leukemia, 11, 19091914.
  • Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 49904997.
  • Clavio, M., Miglino, M., Spriano, M., Pietrasanta, D., Vallebella, E., Celesti, L., Canepa, L., Pierri, I., Cavaliere, M., Ballerini, F., Beltrami, G., Rossi, E., Vimercati, R., Bruni, R., Congiu, M., Nati, S., Damasio, E., Santini, G. & Gobbi, M. (1998) First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. European Journal of Haematolology, 61, 197203.
  • Esteve, J., Villamor, N., Colomer, D., Cervantes, F., Campo, E., Carreras, E. & Montserrat, E. (2001) Stem cell transplantation for chronic lymphocytic leukemia: diffrent outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia, 15, 445451.
  • Esteve, J., Villamor, N., Colomer, D. & Montserrat, E. (2002) Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood, 99, 18731874.
  • Huhn, D., Von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Serke, S., Peschel, C. & Emmerich, B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, 13261331.
  • Khouri, I.F., Keating, M.J., Vriesendorp, H.M., Reading, C.L., Przepiorka, D., Huh, Y.O., Andersson, B.S., Van Besien, K.W., Mehra, R.C. & Giralt, S.A. (1994) Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. Journal of Clinical Oncology, 12, 748758.
  • Magnac, C., Sutton, L., Cazin, B., Laurent, C., Binet, J.L., Merle-Beral, H., Dighiero, G. & Maloum, K. (1999) Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematology and Cell Therapy, 41, 1318.
  • Noy, A., Verma, R., Glenn, M., Maslak, Z.U., Keenan, J.R., Weiss, M., Filippa, D. & Zelenetz, A.D. (2001) Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment protocol. Blood, 97, 19291936.
  • Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D. & Mellstedt, H. (1997) Phase II multicenter study of CD52 antibody in previousely treated chronic lymphocytic leukemia: European Study Group of Campath-1H Treatment in Chronic Lymphocytic leukemia. Journal of Clinical Oncology, 15, 15671574.
  • Owen, R.G., Goulden, N.J., Oakhill, A., Shiach, C., Evans, P.A., Potter, M.N. & Morgan, G.J. (1997) Comparison of fluorescent consensus IgH PCR and allele-specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL. British Journal of Haematology, 97, 457459.
  • Pedersen, I.M., Buhl, A.M., Klausen, P., Geisler, C.H. & Jurlander, J. (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood, 99, 13141319.
  • Provan, D., Bartlett-Pandite, L., Zwicky, C., Neuberg, D., Maddocks, A., Corradini, P., Soiffer, R., Ritz, J., Nadler, L.M. & Gribben, J.G. (1996) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 88, 22282235.
  • Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001) Quantitative of minimal disease levels in chronic lymphocytic leukemia using a sentive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 2935.
  • Sutton, L., Maloum, K., Gonzalez, H., Zouabi, H., Azar, N., Boccaccio, C., Charlotte, F., Cosset, J., Gabarre, J., Leblond, V., Merle-Beral, H. & Binet, J.L. (1998) Autolougous hematopoietic stem cell transplantation as as salvage treatment for advanced B cells chronic lymphocytic leukemia. Leukemia, 12, 16991707.
  • Vuillier, F., Claisse, J.F., Vandenvelde, C., Travade, P., Magnac, C., Chevret, S., Desablens, B., Binet, J.L. & Dighiero, G. (1992) Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leukemia and Lymphoma, 7, 195204.